Takeda Pharmaceutical Company Limited Stock London S.E.
Stocks
0A87
US8740602052
Pharmaceuticals
OTC Markets Traded|
Delayed
London S.E.
09:30:01 2026-06-15 EDT
|
5-day change | 1st Jan Change | ||
| 15.80 USD | +0.83% |
|
-.--% | +9.58% |
| 04:26am | Takeda Pharmaceutical Says US FDA Approves Rusfertide for Rare Type of Blood Cancer | MT |
| 11:42pm | Takeda Pharmaceutical Wins US Approval for New PV Treatment MIMRYLO | MT |
| Market Cap | 9,261B 57.89B 49.89B 46.77B 42.7B 80.43B 5,533B 80.69B 555B 217B 2,793B 217B 213B | P/E 2027 * |
46.3x | P/E 2028 * | 29.7x |
|---|---|---|---|---|---|
| Enterprise Value | 13,168B 82.31B 70.93B 66.5B 60.71B 114B 7,867B 115B 789B 308B 3,971B 309B 302B | EV / Sales 2027 * |
2.8x | EV / Sales 2028 * | 2.72x |
| Free-Float |
99.26% | Yield 2027 * |
3.52% | Yield 2028 * | 3.59% |
Last Transcript : Takeda Pharmaceutical Company Limited
| 1 day | +0.83% | ||
| 3 months | -2.26% | ||
| 6 months | -12.41% | ||
| Current year | +9.58% |
| Current year | 15.67 |  | 18.29 |
| 1 year | 14.05 | | 18.29 |
| 3 years | 12.59 | | 18.29 |
| 5 years | 12.3 | | 18.29 |
| 10 years | 12.3 | | 19.92 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 2024-12-31 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 2024-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 2022-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 2015-05-31 |
Steven Gillis
BRD | Director/Board Member | 73 | 2018-12-31 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 2024-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.83% | -.--% | - | - | 57.89B | |
| -0.13% | -6.44% | +60.34% | +114.35% | 1,047B | |
| +0.85% | -0.81% | +51.29% | +63.71% | 646B | |
| -1.03% | -3.58% | +21.43% | +72.25% | 451B | |
| -0.52% | -3.62% | +37.20% | +37.15% | 355B | |
| 0.00% | -2.40% | +21.84% | +38.53% | 291B | |
| -1.19% | -2.21% | +1.53% | +11.51% | 252B | |
| -1.05% | -1.57% | +50.30% | +67.68% | 234B | |
| -0.92% | -2.12% | -19.78% | -54.02% | 203B | |
| -2.14% | -0.30% | +28.95% | +87.59% | 181B | |
| Average | -0.52% | -2.68% | +28.12% | +48.75% | 406.59B | |
| Weighted average by Cap. | -0.35% | -3.46% | +37.96% | +65.99% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,695B 29.35B 25.29B 23.71B 21.64B 40.77B 2,805B 40.9B 281B 110B 1,416B 110B 108B | 4,773B 29.84B 25.71B 24.11B 22B 41.45B 2,852B 41.58B 286B 112B 1,439B 112B 110B |
| Net income | 195B 1.22B 1.05B 985M 899M 1.69B 117B 1.7B 11.69B 4.56B 58.83B 4.58B 4.48B | 318B 1.99B 1.72B 1.61B 1.47B 2.77B 190B 2.77B 19.08B 7.45B 96.05B 7.47B 7.31B |
| Net Debt | 3,907B 24.42B 21.04B 19.73B 18.01B 33.93B 2,334B 34.04B 234B 91.33B 1,178B 91.68B 89.69B | 3,703B 23.15B 19.95B 18.7B 17.07B 32.16B 2,212B 32.27B 222B 86.57B 1,117B 86.91B 85.02B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-28 | US$0.000000 | - | 83 |
| 26-08-27 | US$0.000000 | - | 666 |
| 26-08-26 | US$0.000000 | - | 1,490 |
| 26-08-24 | US$0.000000 | - | 149 |
| 26-08-21 | US$0.000000 | - | 1,562 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
- 0A87 Stock
Select your edition
All financial news and data tailored to specific country editions
